JWH-365

JWH-365

0JWH-365 is a synthetic cannabinoid from the naphthoylindole family, which acts as a potent cannabinoid receptor agonist. It was developed by the team led by John W. Huffman at Clemson University.

Chemistry

JWH-365 is a member of the naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as JWH-018 and JWH-073, but it has a unique chemical structure that distinguishes it from these other compounds. JWH-365 is characterized by a naphthoyl group, an indole core, and a substituent at the 3-position of the indole ring.

Pharmacology

JWH-365 acts as a potent agonist at the CB1 receptor and CB2 receptor, the two main cannabinoid receptors in the body. It has a high affinity for these receptors, which means it binds to them strongly and activates them effectively. This receptor activation is responsible for the drug's psychoactive effects.

Effects

The effects of JWH-365 are similar to those of cannabis, due to its action on the cannabinoid receptors. These effects can include relaxation, euphoria, altered perception, and in some cases, hallucinations. However, as a synthetic cannabinoid, JWH-365 can also produce adverse effects such as anxiety, paranoia, and in rare cases, psychosis.

Legal Status

The legal status of JWH-365 varies by country. In many jurisdictions, it is classified as a controlled substance due to its psychoactive properties and potential for abuse. However, because it is a synthetic compound, it may not be specifically listed in all drug laws, and its legal status may be subject to interpretation.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman